So, because we've already run a Phase II MASH/NASH trial and this mouse study shows that we perform better than Resmetrirom, are we really limited to partnering with Madrigal? Couldn't any BP come in and fund our Phase III MASH study? Shouldn't we be open to the highest bidder right now for a partnership in MASH or am I missing something?